Treatment of disseminated cancer by intravenous hydroxyurea and autogenous bone‐marrow transplants: Experience with 35 patients | Zendy

Ariel Irving M. | Zendy

Premium

Treatment of disseminated cancer by intravenous hydroxyurea and autogenous bone‐marrow transplants: Experience with 35 patients

Author(s) -

Ariel Irving M.

Publication year - 1975

Publication title -

journal of surgical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.201

H-Index - 111

eISSN - 1096-9098

pISSN - 0022-4790

DOI - 10.1002/jso.2930070502

Subject(s) - medicine , bone marrow transplant , bone marrow , hydroxycarbamide , haematopoiesis , cancer , bone marrow suppression , drug , blood cancer , intravenous infusions , surgery , bone marrow transplantation , chemotherapy , anesthesia , pharmacology , stem cell , biology , genetics

Massive doses of hydroxyurea (Hydrea) were given to 35 patients suffering from different cancers. Protection to the hematopoietic system was obtained by autogenous marrow transfusions. The clinical response obtained was not considered superior to the results obtained by administering the drug orally over a prolonged period. The described technique is safe and relatively atraumatic, and it may be advisable to administer a large priming dose by this technique to be followed by smaller maintenance doses of a given anticancer chemotherapeutic agent.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research